| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette`s Disorder.
Caring physicians, caring for people. cCARE, Californias largest private practice oncology group, focuses on compassion, prevention, research and wellness.
Since 1980, we have been offering our clients experienced and compassionate clinical care, which gives us the distinction of having served the people of Chesterfield longer than any other private mental health group practice in the county. Our staff of...
All-american Allergy Alternatives is a Appleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.